Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Jun;29(6):997–1004. doi: 10.1128/aac.29.6.997

In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations.

P Van der Auwera, A M Ceuppens, C Heymans, F Meunier
PMCID: PMC180491  PMID: 3729367

Abstract

A new method combining automatic turbidimetry and sequential viable count determinations was developed to evaluate the in vitro activity of various antifungal agents alone and in combination against three clinical isolates of Candida spp. (two Candida albicans and one C. tropicalis) at two inocula (10(-5) and 10(-6) CFU/ml). Specific parameters were derived from the time-kill curves: the maximal rate of killing, the lowest biomass, and the overnight biomass. Their intra-assay and between-assay reproducibilities were high, with respective standard deviations of 0.4 and 0.25 to 1.4 log CFU/ml. Amphotericin B alone showed a linear relationship between rate of killing or lowest biomass and the log of concentration from 0.03 to 4 mg/liter that was similar for the three strains tested. 5-Fluorocytosine (flucytosine) alone showed a dose-related reduction of overnight biomass for concentrations up to 8 mg/liter with no further increase at higher concentrations for one strain of C. albicans and a paradoxical decrease for one strain of C. tropicalis. Ketoconazole alone was found to be only fungistatic with no increased activity at concentrations up to 16 mg/liter. Amphotericin B plus flucytosine interacted synergistically in 46 to 60% of the combinations tested against C. tropicalis depending on the initial inoculum. Indifference was observed for the two strains of C. albicans. Amphotericin B or flucytosine plus ketoconazole was usually indifferent against the three tested strains.

Full text

PDF
997

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayer A. S., Edwards J. E., Jr, Guze L. B. Experimental intraabdominal candidiasis in rabbits: therapy with low-total-dose intravenous amphotericin B. Antimicrob Agents Chemother. 1981 Jan;19(1):179–184. doi: 10.1128/aac.19.1.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calhoun D. L., Roberts G. D., Galgiani J. N., Bennett J. E., Feingold D. S., Jorgensen J., Kobayashi G. S., Shadomy S. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol. 1986 Feb;23(2):298–301. doi: 10.1128/jcm.23.2.298-301.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Drutz D. J., Spickard A., Rogers D. E., Koenig M. G. Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. Am J Med. 1968 Sep;45(3):405–418. doi: 10.1016/0002-9343(68)90075-2. [DOI] [PubMed] [Google Scholar]
  4. Ernst J. D., Rusnak M., Sande M. A. Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S626–S630. doi: 10.1093/clinids/5.supplement_3.s626. [DOI] [PubMed] [Google Scholar]
  5. Galgiani J. N., Stevens D. A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother. 1976 Oct;10(4):721–728. doi: 10.1128/aac.10.4.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Galgiant J. N., Stevens D. A. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother. 1978 Feb;13(2):249–254. doi: 10.1128/aac.13.2.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Graybill J. R., Ahrens J. Interaction of rifampin with other antifungal agents in experimental murine candidiasis. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S620–S625. doi: 10.1093/clinids/5.supplement_3.s620. [DOI] [PubMed] [Google Scholar]
  8. Hamilton J. D., Elliott D. M. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis. 1975 Feb;131(2):129–137. doi: 10.1093/infdis/131.2.129. [DOI] [PubMed] [Google Scholar]
  9. Kobbayashi G. S., Medoff G., Schlessinger D., Kwan C. N., Musser W. E. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science. 1972 Aug 25;177(4050):709–710. doi: 10.1126/science.177.4050.709. [DOI] [PubMed] [Google Scholar]
  10. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  11. Marriott M. S. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J Gen Microbiol. 1980 Mar;117(1):253–255. doi: 10.1099/00221287-117-1-253. [DOI] [PubMed] [Google Scholar]
  12. Mas J., Piña E. Disappearance of nystatin resistance in Candida mediated by ergosterol. J Gen Microbiol. 1980 Mar;117(1):249–252. doi: 10.1099/00221287-117-1-249. [DOI] [PubMed] [Google Scholar]
  13. Medoff G. Antifungal action of rifampin. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S614–S619. doi: 10.1093/clinids/5.supplement_3.s614. [DOI] [PubMed] [Google Scholar]
  14. Medoff G., Comfort M., Kobayashi G. S. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med. 1971 Nov;138(2):571–574. doi: 10.3181/00379727-138-35943. [DOI] [PubMed] [Google Scholar]
  15. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Odds F. C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982 Nov;22(5):763–770. doi: 10.1128/aac.22.5.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shadomy S. In vitro studies with 5-fluorocytosine. Appl Microbiol. 1969 Jun;17(6):871–877. doi: 10.1128/am.17.6.871-877.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Solomkin J. S., Flohr A., Simmons R. L. Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B. Ann Surg. 1982 Feb;195(2):177–185. doi: 10.1097/00000658-198202000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis. 1983 Jun;147(6):1070–1077. doi: 10.1093/infdis/147.6.1070. [DOI] [PubMed] [Google Scholar]
  20. Utz J. P. Chemotherapy of the systemic mycoses. Med Clin North Am. 1982 Jan;66(1):221–233. doi: 10.1016/s0025-7125(16)31455-9. [DOI] [PubMed] [Google Scholar]
  21. Van den Bossche H., Willemsens G., Cools W., Cornelissen F., Lauwers W. F., van Cutsem J. M. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother. 1980 Jun;17(6):922–928. doi: 10.1128/aac.17.6.922. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES